Russell Kelley active positions
| Companies | Position | Start | End |
|---|---|---|---|
Opus Genetics, Inc.
 Opus Genetics, Inc. BiotechnologyHealth Technology Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021. | Director/Board Member | 31/01/2021 | - |
| Founder | 31/01/2021 | - | |
Nacuity Pharmaceuticals, Inc.
 Nacuity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nacuity Pharmaceuticals, Inc. develops and markets pharmaceutical products. The company is headquartered in Fort Worth, TX. | Director/Board Member | 07/11/2022 | - |
| Retinal Degeneration Fund | Corporate Officer/Principal | - | - |
Career history of Russell Kelley
Training of Russell Kelley
| Duke University | Masters Business Admin |
Statistics
International
| United States | 5 |
Operational
| Director/Board Member | 2 |
| Founder | 1 |
| Masters Business Admin | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 3 |
|---|---|
Opus Genetics, Inc.
Opus Genetics, Inc. BiotechnologyHealth Technology Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021. | Health Technology |
Nacuity Pharmaceuticals, Inc.
Nacuity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nacuity Pharmaceuticals, Inc. develops and markets pharmaceutical products. The company is headquartered in Fort Worth, TX. | Health Technology |
| Retinal Degeneration Fund |
- Stock Market
- Insiders
- Russell Kelley
- Experience